Parkinson's Disease: World Drug Market 2011-2021


September 26, 2011
142 Pages - SKU: VSG6653333
License type:
Countries covered: Global

Parkinson's Disease: World Drug Market 2011-2021

  enlarge


What are the commercial prospects for the treatment of Parkinson's disease? Visiongain's report shows you potential drug revenues to 2021. Find opportunities and forecasts.

Do you want revenue predictions for Parkinson's disease treatments at total world, submarket, product and national levels to 2021? Through our research and analysis we aim to save you time and help in your decisions.

Find out how the drugs Stalevo/Comtess, Sifrol, Azilect and Requip can perform to 2021, seeing potential revenues. We cover revenues for dopaminergic agents, dopamine agonists, COMT inhibitors, MAO inhibitors and other drugs for Parkinson's disease.

We discuss Boehringer Ingelheim, Novartis, GSK, Teva and many other companies. Receive industry and market information you need.

The Parkinson's treatment market has potential to expand. In 2011 there are more than 300 late-stage trials of Parkinson's drugs in progress. Find R&D trends.

Our report provides data, analysis and opinion to benefit your research, calculations, meetings and presentations. You can find answers now in our work.

Revenue forecasts, market shares, developmental trends, discussions and interviews

In our report you find revenue forecasts, growth rates, market shares, qualitative analyses (incl. SWOT), an R&D review and opinions from our survey. You receive 114 tables and charts and two research interviews (see the table of contents).

Advantages of Parkinson's Disease: World Drug Market 2011-2021 for your work

Our report gives you the following advantages in particular:
  • Find revenue predictions to 2021 for the world Parkinson's disease drug market and submarkets, seeing revenue growth
  • Discover revenue forecasts to 2021 for leading products, assessing market potentials
  • Assess leading companies, discovering their activities and prospects
  • See revenue forecasts to 2021 for leading national markets - US, Japan, UK, Germany, France, Spain, Italy, China and India
  • Review R&D for treating Parkinson's disease, seeing pipeline trends
  • Investigate competition and opportunities influencing the industry and market
  • See what will stimulate and restrain the industry and market from 2011
  • View opinion from our survey, receiving detailed interview transcripts.
There, you find a distinctive mix of quantitative and qualitative analysis with independent predictions. We tackle crucial questions on Parkinson's disease, helping you to stay ahead.

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

The publisher is using a password system to access all reports. This password will be set up for single user and departmental licenses and will be emailed out to the client at the same time as the report. In the case of departmental site license purchases, the publisher requires all email addresses for the licensed users prior to fulfillment.


Additional Information


Report Excerpt

5.7 Rest of the World: Market Forecast 2011-2021

The revenues of the ‘Rest of the World’ market are predominantly derived from the developed markets of the Anglosphere, particularly New Zealand, Australia, and Canada, although the other two BRIC (Brazil, Russia, India and China) countries are also showing strong growth.

Companies Listed

Abbott Laboratories
Acadia Pharmaceuticals
Amgen
Axxonis Pharma
Biotie
BioSante Pharmaceuticals
Biovail
Boehringer Ingelheim
Brainstorm Cell Therapeutics
Buck Institute for Research on Aging
Ceregene
Chelsea Therapeutics
Ciba-Geigy
Cipla
Columbia University
Dainippon Sumitomo
Dresden University of Technology
Eisai
EMEA/EMA
Endo Pharmaceuticals
Erba
Farmitalia Carlo
FDA [US]
Impax Laboratories
GlaxoSmithKline
Ipsen
Juvantia Pharma
Kaneka Nutrients
Kyowa Hakko Kirin
Lundbeck
Maypro Industries
Merck & Co.
Merck KGaA
Merck Serono
Mitsubishi Gas Chemical
Mylan
National Institute of Neurological Disorders and Stroke [NINDS]
Neupro
Neurologix
Newron Pharmaceuticals
NINDS
Novartis
Orion
Oxford BioMedica
Pacific Rainbow International
Parkinson's UK
Parr
Pfizer
Pharmacia
Roche
Roxane
Sandoz
Santhera
Schering Plough
Servier
ShenZhou Biology & Technology
Solvay Pharmaceuticals
Sun Pharmaceuticals
Synergen Corporation
Synosia Therapeutics
Teva Pharmaceutical Industries
UCB
University of Bristol Institute of Clinical Neuroscience
University of Kentucky
University of Nebraska
University of Rochester
Valeant
Watson Pharmaceuticals
Weill Medical College, Cornell University
Wockhardt
Xenoport
Xiamen Kingdomway Group
Zhejiang Medicine Company

More Parkinson's Disease reports by Visiongain

Neuroprotective Products: World Market Prospects 2012-2022 by Visiongain
What are the commercial prospects for neuroprotective treatments? Visiongain's new report shows you potential revenues and trends to 2022, discussing data, opportunities and outlooks. ...
See all reports like this >>

More Global Parkinson's Disease reports

Parkinson's Disease Global Clinical Trials Review, H2, 2012 by GlobalData
Parkinson's Disease Global Clinical Trials Review, H2, 2012SummaryGlobalData's clinical trial report, “Parkinson’s Disease Global Clinical Trials Review, H2, 2012\ provides data on the Parkinson’s Disease ...
Vaccines 2012-16 World Market Analysis, Key Players, Trends, Pediatric and Adult Segments by Kalorama Information
This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for ...
Global Markets for Treatments of Dementia and Movement Disorders - Focus on Movement Disorders by BCC Research
The global market for treatments for syndromes of dementia and movement disorders was valued at $10.5 billion in 2011 and should reach $11.1 billion in ...
Analyzing the Global CNS Market by Aruvian's R'search
The CNS market at a global scale is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms remain favorable within ...
See all reports like this >>